Biocure Technology Inc. (BICTF)
USD 0.0
(-95.51%)
USD 0.0
(-95.51%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 41.87 Thousand CAD | -48.42% |
| 2022 | 81.18 Thousand USD | -97.23% |
| 2021 | 2.92 Million CAD | -5.45% |
| 2020 | 3.09 Million CAD | 12.17% |
| 2019 | 2.75 Million CAD | 58.42% |
| 2018 | 1.74 Million CAD | 274.25% |
| 2017 | 465.51 Thousand CAD | 25.68% |
| 2016 | 370.39 Thousand CAD | -80.76% |
| 2015 | 1.92 Million CAD | 3837.74% |
| 2014 | 48.9 Thousand CAD | 276.15% |
| 2013 | 13 Thousand CAD | -83.86% |
| 2012 | 80.53 Thousand CAD | 519.46% |
| 2011 | 13 Thousand CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 43.67 Thousand USD | 4.3% |
| 2024 Q2 | 33.28 Thousand USD | 4.3% |
| 2023 Q2 | 83.95 Thousand USD | 1.72% |
| 2023 Q1 | 82.53 Thousand USD | 1.66% |
| 2023 Q4 | 41.87 Thousand USD | -50.99% |
| 2023 Q3 | 85.44 Thousand USD | 1.78% |
| 2023 FY | 41.87 Thousand CAD | -48.42% |
| 2022 Q4 | 81.18 Thousand USD | -94.49% |
| 2022 FY | 81.18 Thousand USD | -97.23% |
| 2022 Q1 | 1.73 Million CAD | -40.81% |
| 2022 Q2 | 1.62 Million CAD | -6.47% |
| 2022 Q3 | 1.47 Million CAD | -9.03% |
| 2021 Q4 | 2.92 Million CAD | 0.91% |
| 2021 Q2 | 3.18 Million CAD | 3.26% |
| 2021 FY | 2.92 Million CAD | -5.45% |
| 2021 Q1 | 3.08 Million CAD | -22.65% |
| 2021 Q3 | 2.9 Million CAD | -9.01% |
| 2020 Q1 | 3.67 Million CAD | 0.54% |
| 2020 FY | 3.09 Million CAD | 12.17% |
| 2020 Q2 | 3.58 Million CAD | -2.2% |
| 2020 Q4 | 3.99 Million CAD | 3.92% |
| 2020 Q3 | 3.84 Million CAD | 6.99% |
| 2019 Q1 | 1.69 Million CAD | -2.8% |
| 2019 Q2 | 2.17 Million CAD | 28.35% |
| 2019 Q4 | 3.65 Million CAD | 51.13% |
| 2019 Q3 | 2.41 Million CAD | 11.15% |
| 2019 FY | 2.75 Million CAD | 58.42% |
| 2018 Q2 | 868.52 Thousand CAD | 77.58% |
| 2018 Q4 | 1.74 Million CAD | 103.26% |
| 2018 FY | 1.74 Million CAD | 274.25% |
| 2018 Q1 | 489.09 Thousand CAD | 5.07% |
| 2018 Q3 | 857.13 Thousand CAD | -1.31% |
| 2017 Q3 | 66 Thousand CAD | 40.43% |
| 2017 FY | 465.51 Thousand CAD | 25.68% |
| 2017 Q1 | - CAD | -100.0% |
| 2017 Q2 | 47 Thousand CAD | 0.0% |
| 2017 Q4 | 465.51 Thousand CAD | 605.33% |
| 2016 FY | 370.39 Thousand CAD | -80.76% |
| 2016 Q4 | 1.01 Million CAD | 975.21% |
| 2016 Q3 | 94.7 Thousand CAD | 10.12% |
| 2016 Q2 | 86 Thousand CAD | 15.9% |
| 2016 Q1 | 74.2 Thousand CAD | 0.68% |
| 2015 FY | 1.92 Million CAD | 3837.74% |
| 2015 Q3 | 8000.00 CAD | 0.0% |
| 2015 Q4 | 73.7 Thousand CAD | 821.25% |
| 2015 Q1 | 48.9 Thousand CAD | 32.16% |
| 2015 Q2 | 8000.00 CAD | -83.64% |
| 2014 Q2 | 23 Thousand CAD | 76.92% |
| 2014 Q1 | 13 Thousand CAD | 62.5% |
| 2014 Q3 | 32.1 Thousand CAD | 39.57% |
| 2014 Q4 | 37 Thousand CAD | 15.26% |
| 2014 FY | 48.9 Thousand CAD | 276.15% |
| 2013 Q3 | 97.53 Thousand CAD | 11.42% |
| 2013 Q4 | 8000.00 CAD | -91.8% |
| 2013 FY | 13 Thousand CAD | -83.86% |
| 2013 Q1 | 80.53 Thousand CAD | 0.0% |
| 2013 Q2 | 87.53 Thousand CAD | 8.69% |
| 2012 FY | 80.53 Thousand CAD | 519.46% |
| 2012 Q2 | - CAD | -100.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q1 | 13 Thousand CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 FY | 13 Thousand CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Qrons Inc. | 351.84 Thousand USD | 88.099% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.859% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | 65.816% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -62.817% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.794% |
| BioStem Technologies, Inc. | 4.71 Million USD | 99.111% |
| CSL Limited | 12.18 Billion USD | 100.0% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 99.287% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.903% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.908% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 94.462% |
| Skye Bioscience, Inc. | 4.61 Million USD | 99.093% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | 310 Thousand USD | 86.492% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 93.354% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.898% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 98.984% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 89.579% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.848% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 98.2% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 95.584% |
| Mesoblast Limited | 118.7 Million USD | 99.965% |
| Marizyme, Inc. | 18.71 Million USD | 99.776% |
| Genus plc | 233.1 Million USD | 99.982% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 98.571% |
| Pharming Group N.V. | 171.54 Million USD | 99.976% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 95.285% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 96.883% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 94.417% |
| ContraFect Corporation | 2.88 Million USD | 98.547% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | 69.093% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 97.105% |
| IMV Inc. | 28.88 Million USD | 99.855% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 99.26% |
| MultiCell Technologies, Inc. | 202.58 USD | -20570.846% |
| ONE Bio Corp. | 19.71 Million USD | 99.788% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.927% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | 97.199% |
| Q BioMed Inc. | 4.1 Million USD | 98.981% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.873% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 96.591% |
| Biomind Labs Inc. | 735.54 Thousand USD | 94.307% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.938% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 98.616% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 99.678% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 88.359% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | 70.41% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 98.146% |
| GB Sciences, Inc. | 1.75 Million USD | 97.62% |
| Alpha Cognition Inc. | 1.22 Million USD | 96.569% |
| HST Global, Inc. | 98.31 Thousand USD | 57.409% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 83.164% |
| Halberd Corporation | 150 Thousand USD | 72.083% |
| Enzolytics Inc. | 996.33 Thousand USD | 95.797% |
| Agentix Corp. | 50 Thousand USD | 16.25% |
| Resverlogix Corp. | 6.49 Million USD | 99.355% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 83.616% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 99.791% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 99.408% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 98.454% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -309.535% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.99% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 79.127% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 98.254% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 81.737% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | 71.831% |
| Kadimastem Ltd | 891.22 Thousand USD | 95.301% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 83.262% |
| LadRx Corporation | 33.6 Thousand USD | -24.606% |
| Cell Source, Inc. | 9.25 Million USD | 99.548% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 94.462% |
| NovAccess Global Inc. | 2.19 Million USD | 98.096% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | 81.664% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 80.152% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 99.16% |
| Mobile Lads Corp. | 484.28 Thousand USD | 91.353% |
| CytoDyn Inc. | 30.07 Million USD | 99.861% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 99.465% |
| SYBLEU INC | 477.5 Thousand USD | 91.23% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 99.116% |
| International Stem Cell Corporation | 4.17 Million USD | 98.998% |
| Bioxytran, Inc. | 1.92 Million USD | 97.825% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 32.907% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 98.08% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 99.496% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 99.512% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 97.308% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 84.375% |
| Neutra Corp. | 54.15 Thousand USD | 22.677% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 97.712% |
| PureTech Health plc | 25.51 Million USD | 99.836% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 96.579% |
| IXICO plc | 472.02 Thousand USD | 91.129% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 99.73% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.933% |
| CSL Limited | 12.18 Billion USD | 100.0% |
| Cellectis S.A. | 92.77 Million USD | 99.955% |